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Cholangiocytes, the lining epithelial cells in bile ducts, are 
an important subset of liver cells. They are activated by 
endogenous and exogenous stimuli and are involved in the 
modification of bile volume and composition. They are also 
involved in damaging and repairing the liver. Cholangiocytes 
have many functions including bile production. They are also 
involved in transport processes that regulate the volume and 
composition of bile. Cholangiocytes undergo proliferation 
and cell death under a variety of conditions. Cholangiocytes 
have functional and morphological heterogenecity. The im-
munobiology of cholangiocytes is important, particularly for 
understanding biliary disease. Secretion of different proin-
flammatory mediators, cytokines, and chemokines suggests 
the major role that cholangiocytes play in inflammatory reac-
tions. Furthermore, paracrine secretion of growth factors and 
peptides mediates extensive cross-talk with other liver cells, 
including hepatocytes, stellate cells, stem cells, subepithelial 
myofibroblasts, endothelial cells, and inflammatory cells. 
Cholangiopathy refers to a category of chronic liver diseases 
whose primary disease target is the cholangiocyte. Cholan-
giopathy usually results in end-stage liver disease requiring 
liver transplant. We summarize the biology of cholangiocytes 
and redefine the concept of cholangiopathy. We also discuss 
the recent progress that has been made in understanding 
the pathogenesis of cholangiopathy and how such progress 
has influenced therapy. (Gut Liver 2016;10:687-698)
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INTRODUCTION
The biliary system is comprised of intrahepatic bile ducts, ex-
trahepatic bile ducts and the gallbladder. Bile is transported by 
the extensive biliary tract, which measures approximately 2 km 
in human. A layer of epithelial cells called cholangiocytes lines 
the intrahepatic bile ducts of this extensive network. The ex-
trahepatic ductal epithelial cells and gallbladder epithelial cells 
(GBECs) share many features with cholangiocytes. Cholangio-
cytes comprise only about 3% to 5% of the total cell mass of the 
liver, but they are crucial for normal physiologic processes, and 
they contribute to multiple disease states of the biliary tract.1-5
Cholangiocytes serve several functions performed by several 
important molecules. Most importantly, cholangiocytes partici-
pate in the formation and transportation of bile via transmem-
brane molecules that are expressed on the apical or basolateral 
membrane. These transporters include channels (i.e., water 
channels [aquaporins]), transporters (i.e., SGLT1: Na+-glucose 
transporter), and exchangers (i.e., SLC4A2: Cl–/HCO3
– exchanger). 
Impairing these molecules could lead to cholestasis (Fig. 1).6-8 
Cholangiocytes also interact with resident and nonresident cells 
of the bile ducts via inflammatory and fibrotic mediators, such 
as tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6). On 
the other hand, diseased cholangiocytes can cause biliary in-
flammation and fibrosis. Finally, cholangiocytes are involved in 
cell-cycle phenomena that maintain tissue homeostasis in the 
biliary system via modulators of apoptosis (i.e., AkT1: protein 
kinase B α), senescence (i.e., N-RAS transforming protein), and 
proliferation (i.e., platelet-derived growth factor). Damage to the 
cholangiocytes may result in ductopenia, dysplasia, or malig-
nant transformation of the bile ducts (Fig. 2).6-8
Unlike other epithelial cells, cholangiocytes are morphologi-
cally and functionally heterogeneous.9,10 Small cholangiocytes 
possess proliferative capabilities and display functional plasticity 
in disease, while large cholangiocytes are involved in hormone-
regulated bile secretion. Stem cells in the peribiliary glands that 
can differentiate into cholangiocytes may be involved in biliary 
remodeling and pathogenesis of cholangiopathies.11,12 Under-
standing the biology of cholangiocytes allows us to understand 
the mechanisms of cholangiopathy (Fig. 2) and to develop ad-
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equate treatment for these diseases. 
Findings from electron microscopy of cholangiocytes show 
the apical microvilli facing the lumen of the bile duct and vari-
ous micro-organelles, such as the rough endoplasmic reticulum, 
mitochondria, vesicles, and nucleus in cytoplasm. From such 
findings, we can speculate that cholangiocytes are incredibly 
versatile and complex in their functions. The cholangiocyte 
indeed has many functions, which can be categorized into four 
broad areas. Firstly, cholangiocytes are involved in transport 
processes that regulate the volume and composition of bile. 
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Fig. 1. Biology of cholangiocytes.6,7,43,44 Various molecules conduct several important functions in cholangiocytes. Bile is formed through the 
activity of transmembrane molecules, such as channels, transporters, and exchangers. Dysfunction of these molecules may lead to cholestasis. 
Cholangiocytes interact with resident and nonresident cells of bile ducts via inflammatory and fibrotic mediators, such as tumor necrosis factor α 
and interleukin 6, which, in disease states, results in biliary inflammation and fibrosis. Cholangiocytes contribute to the cell-cycle phenomena that 
maintain tissue homeostasis via modulators of apoptosis, senescence, and proliferation. In disease states, these processes may result in ductopenia, 
dysplasia, and malignant transformation of the bile ducts. 
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Fig. 2. Pathogenic model of cholangiopathy.6,7,43,44 Cholangiocytes interact with endogenous or exogenous substances, microorganisms, or envi-
ronmental factors. The initial host response is the development of a reactive cholangiocyte and a proinflammatory microenvironment. The balance 
of the host response to insult depends on genetic susceptibility, epigenetics, and posttranscriptional regulation, and it may result in the resolution 
of the disease state or the perpetuation of the initial inflammatory response. This may result in chronic inflammation of the bile ducts and ulti-
mately to cholestasis, bile duct proliferation, ductopenia, fibrosis, and the potential malignant transformation of cholangiocytes.
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Secondly, cholnagiocytes undergo proliferation and cell death 
under a variety of conditions, some of which are important 
in our understanding of disease states. Thirdly, the concept of 
cholangiocyte heterogeneity has attracted attention, as not all 
cholangiocytes are functionally or morphologically identical. Fi-
nally, the immunobiology of the cholangiocyte is important for 
understanding diseases characterized by vanishing bile ducts, 
such as primary biliary cirrhosis (PBC), primary sclerosing chol-
angitis (PSC), allograft rejection, and graft-versus-host disease 
(GVHD).1-4,13,14
CHOLANGIOPATHY
Based on the importance of cholangiocytes in normal hepa-
tobiliary physiology emerged the idea of cholangiopathy—a dis-
ease state that is characterized by abnormalities in cholangio-
cyte function. Cholangiopathy can be generally classified into 
immune-mediated states (some of which are characterized by the 
vanishing bile duct syndromes), infectious, genetic, idiopathic, 
malignant, and secondary sclerosing cholangitis (Table 1).6 To 
understand the variety in cholangiopathy, a review of cholan-
giocyte biology is crucial.1,4,5,15-18
Each type of cholangiopathy has a unique manifestation and 
clinical course, yet they share common processes that involve 
proinflammatory signaling, innate immune responses, cholan-
giocyte proliferation and differentiation, as well as tissue repair 
processes.6 
Cholangiocytes are activated by various insults, which then 
increase expression of proinflammatory cytokines and che-
mokines (e.g., IL-6, IL-8, TNF-α, and various growth factors).19 
The released molecules act in autocrine and paracrine manners, 
and ultimately lead to cholangiocyte proliferation, apoptosis, 
Table 1. Classification of Cholangiopathy1,6
Immune mediated
    Hepatic allograft rejection
    GVHD   
    PBC
    Autoimmune cholangitis 
    PSC  
Idiopathic or immune mediated
    Autoimmune cholangitis 
    Biliary atresia* 
    Idiopathic childhood/adulthood ductopenia 
    IgG4-associated cholangitis 
    PBC* 
    PSC*
Infectious
    Viral (incl. HIV-associated cholangitis)
    Bacterial
    Fungal
    Parasitic
    Protozoan
Malignant 
    Cholangiocarcinoma
Genetic 
    Alagille syndrome 
    Caroli syndrome 
    Cystic fibrosis 
    Polycystic liver disease 
    ADPLD 
    ADPKD 
    ARPKD
Secondary sclerosing cholangitis 
    ABCB4 deficiency 
    Abdominal trauma (surgical or blunt) 
    AIDS cholangiopathy 
    Amyloidosis 
    Chemical/drugs (i.e., 5-fluorouracil) 
    Choledocholithiasis 
    Eosinophilic or mast cell cholangitis 
    GVHD involving the liver 
    Iatrogenic biliary strictures 
    Portal hypertensive biliopathy 
    Recurrent pyogenic cholangitis 
    Sarcoidosis 
    Sickle cell disease 
    Vascular/ischemic (i.e., hepatic artery stenosis after liver transplant)
GVHD, graft-versus-host disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; HIV, human immunodeficiency virus; AD-
PLD, autosomal dominant polycystic liver disease; ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycys-
tic kidney disease; ABCB, ATP-binding cassette transporter B; AIDS, acquired immunodeficiency syndrome.
*For the genetic component of these diseases.
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senescence, angiogenesis, fibrosis, and the recruitment of innate 
and adaptive immune cells, mesenchymal cells, and endothelial 
cells. Such events result in ductal reactions such as proliferation 
of ductules, infiltration of leukocytes and lymphocytes, activa-
tion of liver progenitor cells, and an increase in matrix protein. 
Eventually, these events result in periportal fibrosis, ductopenia, 
and biliary cirrhosis (Fig. 2).6,20 
The initial host response to various insults is the reactive 
cholangiocyte and the creation of a bile duct proinflammatory 
microenvironment. The host factors likely depend on genetic 
susceptibility, epigenetics, posttranscriptional regulation, or 
other yet unknown mechanisms, may lead to repair/resolution 
or to chronic inflammation of the bile ducts when the initial in-
flammatory response is perpetuated. Cholangiopathy ultimately 
results in cholestasis, bile duct proliferation, ductopenia, fibrosis, 
and potential malignant transformation (Fig. 2).6 
EXPERIMENTAL MODELS
Our understanding of cholangiocyte biology is linked to 
advances in the methodology for studying these cells. Much re-
search has been done in animal models, particularly using rats. 
Cholangiocytes selectively proliferate in response to various in 
vivo methods such as bile duct ligation, dietary manipulation, 
and partial hepatectomy. This allows for cholangiocytes to be 
harvested for further studies. Another advanced method has 
been the isolation of intact bile duct units. This method anables 
in vitro transport studies to be performed. Finally, having cul-
tures of either normal or malignant cholangiocytes allow cell 
biologic studies to be performed.21-24
THE MECHANISMS OF DUCTAL BILE FORMATION
As mentioned earlier, cholangiocytes can contribute up to 
40% of the daily bile output. In the bile duct ligated rat model, 
it was shown that cholangiocytes increased their secretory abil-
ity. Fig. 3 shows some of the important pathways that mediate 
secretory functions of cholangiocyte. Secretin initiates bile for-
mation by binding to its receptor on the basolateral membrane 
and activating the cyclic adenosin mono-phpsphate (cAMP) 
signaling pathway. cAMP is important for activating apical 
chloride channels, which are believed to be cystic fibrosis trans-
membrane conductance regulator. 
This efflux of chloride ions drives bicarbonate secretion by 
activating the chloride/bicarbonate exchanger, called AE2. An 
important component of cholangiocyte secretion is water, and 
specific water channels called aquaporins have been identified. 
Aquaporin 1 resides in intracellular vesicles and is stimulated 
by cAMP to migrate to the apical membrane. In the active state, 
it mediates water efflux from the cell, and somatostatin acts 
to inhibit this process. A separate water channel, aquaporin 4, 
is located on the basolateral side, but its secretory function is 
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Fig. 3. Membrane transporters/receptors/channel proteins in cholangiocytes.1,53-55 The choleretic effect of secretin is mediated by increases in 
cAMP, the activation of cAMP-dependent Cl– channels (CFTR), and the subsequent ductal secretion of bicarbonate. Aquaporin water channels 
(regulated by secretin) appear to play an important role in this process. cAMP-dependent Cl– secretion enables the mobilization of intracellular 
Ca2+ stores and the activation of Ca2+-dependent apical membrane Cl– channels. The NHE1 isoform regulates secretin-stimulated ductal secre-
tion. Numerous hormone/peptide receptors have been identified on the basolateral domain of cholangiocytes. Several of these receptors (VIP and 
bombesin) modulate ductal choleresis, whereas other receptors (gastrin and somatostatin) inhibit basal and secretin-stimulated choleresis. The api-
cally located ABAT enables the entry of bile salts into cholangiocytes, whereas the truncated form of ABAT eliminates bile salts from the basolat-
eral membrane.
AE, anion exchanger; CFTR, cystic fibrosis transmembrane conductance regulator; NHE, sodium-hydrogen exchanger; ASBT, apical sodium-
dependent bile acid transporter; cAMP, cyclic adenosin mono-phpsphate; LPS, lipopolysaccharide; TNF, tumor necrosis factor; IL, interleukin; 
HGF, hepatocyte growth factor; Ach, acetylcholine; INF, interferon; SST, somatostatin; VIP, vasoactive intestinal peptide; ABAT, apical bile acid 
transporter.
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much less than that of apical aquaporin 1.6,7,25-29
Cholangiocytes contribute to the alkalinity of bile by secret-
ing bicarbonate. Apart from CFTR and the anion exchanger 
previously mentioned, there are sodium/hydrogen exchangers 
on the basolateral and apical surface of the cholangiocyte. In 
addition, a sodium/bicarbonate symport mechanism exists at 
the basolateral surface (Fig. 3).6,7,30 Bicarbonate can be converted 
to carbonic acid, and through the action of carbonic anhydrase, 
it can be converted to carbon dioxide and water. Bicarbonate 
efflux from the cell occurs predominantly via the apical anion 
exchanger. Bicarbonate efflux by secretin is responsive to ace-
tylcholine, which increases by intracellular calcium.
HEPATODUCTAL COMMUNICATION: THE ROLE OF ATP
How do hepatocytes communicate with cholangiocytes? An 
emerging theory is that 5’-adenosine triphosphate (ATP) and 
other purines are involved in signaling between these two cell 
types. ATP is secreted by both hepatocytes and cholangiocytes, 
and its binding to purinergic receptors initiates the secretory 
processes outlined earlier, including the secretion of choloride 
and of bicarbonate. ATP acts as both an autocrine and a para-
crine regulator of bile flow in intrahepatic bile ducts.31,32
IONIC CHANNEL ORGANIZATION WITHIN THE  
CHOLANGIOCYTE PLASMA MEMBRANE
Due to the presence of numerous ion channels, the com-
munication and coordination between these plasma membrane 
proteins is another area of investigation. The concept is emerg-
ing that ion channels (and perhaps other integral membrane 
proteins) are arranged in multiprotein complexes that allow for 
a coordinated function. A family of linker proteins called ezrin-
radixin-moesin (ERM) proteins have PDZ (post synaptic density 
protein [PSD95], drosophila disc large tumor suppressor [Dlg1], 
and zonula occludens-1 protein [zo-1]) binding domains that 
allow for protein-protein interactions to take place. These PDZ 
binding domains allow the C-termini of integral membrane 
proteins to bind to EBP50, which in turn binds to an ERM pro-
tein such as ezrin. When bound to the cAMP-sensitive protein, 
kinase A, the ERM protein brings the kinase close to its target. 
ERM proteins also bind to actin, which promotes the formation 
of a cytoskeleton scaffold for these multiprotein complexes. In 
summary, these linker proteins provide a coordinated function 
by bringing different ion channels in close proximity to each 
other and to regulatory proteins.33
BILE ACID TRANSPORT IN CHOLANGIOCYTES  
(THE CHOLEHEPATIC SHUNT)
Another important function of cholangiocytes is their role 
in bile acid transport. Cholangiocytes are exposed to high 
concentrations of bile on their apical side, and bile acids have 
been known to stimulate bile flow. There is now evidence of 
the existence of a cholehepatic shunt pathway that allows for 
the transport of bile acid back to the liver. The apical sodium-
dependent bile acid transporter (ASBT, which is the same as 
the ileal bile acid transporter) has been identified on the apical 
membrane of cholangiocytes. ASBT transports bile acids into 
cholangiocytes where they can have multiple effects. They can 
stimulate a secretin-induced cAMP secretory response as well 
as stimulate bicarbonate secretion. They can be conjugated with 
taurine or glycine; and they can have proliferative effects on 
the cell. A truncated form of the ASBT has been identified on 
the basolateral membrane, and the existence of another sodium-
independent bile acid transporter on the basolateral membrane 
has been identified. The machinery exists in the cholehepatic 
shunt pathway in order to absorb bile acids and transport them 
back to the liver.34,35
MORPHOLOGICAL AND FUNCTIONAL HETEROGENEITY 
OF CHOLANGIOCYTES
Another important concept that has emerged is the mor-
phological and functional heterogenecity of cholangiocytes. 
Small cholangiocytes, taken from bile ducts less than 15 mi-
crons in diameter, look and behave very differently from large 
cholangiocytes, which are taken from bile ducts larger than 15 
microns. Small cholangiocytes are cuboidal, but the larger chol-
angiocytes are more columnar. Moreover, small cholangiocytes 
have inconspicuous organelles and minimal cytoplasm, whereas 
large cholangiocytes have plenty of organelles and a small 
nucleus/cytoplasm ratio. The large, but not the small, cholan-
giocytes have cilia. Small and large cholangiocytes differentially 
express the array of receptors, enzymes and transporters. More 
is known about the function of large cholangiocytes. Large 
cholangiocytes are characterized by the expression of CFTR, the 
anion exchanger, the bile acid transporter, the secretin recep-
tor and proliferative response to bile duct ligation. However, 
small cholangiocytes do not have a hormone regulated ductal 
secretory response, do not respond to bile duct ligation, and are 
resistant to carbon tetrachloride. Small cholangiocytes are more 
resistant to injury: when animals are intoxicated with CCl4, 
large cholangiocytes undergo apoptosis, whereas small cholan-
giocytes proliferate, in a sort of a compensatory attempt. Small 
cholangiocytes can be express the secretin receptor and exhibit 
a secretin-induced cAMP response following the death of large 
cholangiocytes in animal experiment with CCl4.
36-38
CHOLANGIOCYTE PROLIFERATION
Cholangiocyte proliferation can be induced by multiple 
pathways. We have already mentioned that cholangiocyte is a 
proliferative response to bile acids. Additionally, acetylcholine, 
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estrogen, hepatocyte growth factor, and IL-6 all can signal via 
specific receptor binding, which leads to the proliferation. For 
IL-6, there appears to be an autocrine loop that can be initiated 
by proinflammatory cytokines such as TNF-α , and by bacterial 
products like lipopolysaccharide (LPS). There are antiprolifera-
tive mediators as well. Somatostatin, gastrin, and interferon γ 
(IFN-γ) are some of the known antiproliferative agents.39,40 
Stem cells in the peribiliary glands that can differentiate 
into cholangiocytes may be involved in biliary remodeling and 
pathogenesis of cholangiopathies.11,12
CHOLANGIOCYTE APOPTOSIS 
Cholangiocytes can die by programmed cell death, or apop-
tosis. The Fas/Fas ligand system activates apoptosis in cholan-
giocytes, which are capable of expressing both the receptor and 
the ligand. This pathway may be important in PBC. The proto-
zoan, Cryptosporidium parvum also initiates apoptosis through 
this pathway. Glycoursodeoxycholic acid inhibits apoptosis by 
blocking a key protease called caspase 3. The balance between 
the pro-apoptotic BAX and the antiapoptotic bcl-2 also deter-
mines whether a cell lives or dies. Carbon tetrachloride can poi-
son cells by initiating programmed cell death. Finally, blockade 
of the estrogen receptor causes programmed cell death. Under-
standing these pathways is important, not only for certain in-
fections such as that due to C. parvum, but also because insights 
into these cellular mechanisms allow us to better understand 
vanishing bile duct syndromes, such as PBC and GVHD.41,42
IMMUNOBIOLOGY OF CHOLANGIOCYTES
The biliary tract excretes bile into the duodenum and com-
municates with the gastrointestinal tract. Microorganisms pres-
ent in the duodenum can cause ascending infections of the bili-
ary tract.6,7,43,44
The immunobiology of the cholangiocyte is another area of 
intense investigation due to the importance of immune-medi-
ated mechanisms in vanishing bile duct syndromes, infection 
and inflammation. Cholangiocytes participate in the immune 
pathogenesis of both infectious and noninfectious hepatobili-
ary diseases and they play an important role in both innate and 
adaptive immunity. Recognition of pathogen-associated mo-
lecular patterns by Toll-like receptors leads to the secretion of 
antimicrobial peptides, inflammatory cytokines, and the expres-
sion of adhesion molecules that allow for an interplay between 
the innate and adaptive immune responses.6,43 
Cholangiocytes express adhesion molecules, which allow 
their interaction with CD4+ and CD8+ T cells.44,45 Cholangiocytes 
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Fig. 4. Immune properties of cholangiocytes.44 Cholangiocytes express adhesion molecules, which enable their interaction with CD4+ and CD8+ 
T cells. Because of the expression of major histocompatibility complex (MHC)-I and MHC-II on their surface, cholangiocytes are cytotoxic targets 
and/or antigen-presenting cells (APCs). Cholangiocytes produce chemokines and cytokines, which have autocrine or paracrine effects and modu-
late immune reactions. In addition, cholangiocytes secrete metalloproteinases, nitric oxide, and other growth factors involved in immune injury 
and fibrogenesis of the liver. 
LFA, lymphocyte function-associated antigen; TCR, T-cell receptor; BEC, biliary epithelial cell; CTL, cytotoxic T lymphocyte; MMP, matrix metal-
loproteinase; PDGF, platelet-derived growth factor; NO, nitric oxide; TNF, tumor necrosis factor; IL, interleukin; IFN, interferon; TGF, transforming 
growth factor; MCP, monocyte chemotactic protein; IP-10, interferon-inducible protein-10; MIP-2, macrophage inflammatory protein-2; TCA, T-
cell activation gene-3. 
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can also communicate directly with lymphocytes, such as the 
T helper subsets, or cytotoxic T lymphocytes. The presentation 
of antigens on major histocompatibility complex (MHC) class I 
and MHC class II molecules by cholangiocytes in disease states 
such as PBC has been demonstrated; however, there is some 
controversy regarding whether cholangiocytes are true antigen 
presenting cells. The presence of adhesion molecules such as 
intercellular cell adhesion molecule 1 and lymphocyte function-
associated antigen-3 allows for direct cell-cell contact between 
cholangiocytes and lymphocytes, suggesting that cholangiocytes 
play a direct role in the immune response (Fig. 4).46-49 We have 
already mentioned the ability of these cells to secrete and re-
spond to cytokines—examples given here are IL-6 and TNF-α.50
Cholangiocytes produce chemokines and cytokines,50 which 
modulate immune reactions through either autocrine or para-
crine effects. In addition, cholangiocytes secrete metallopro-
teinases, nitric oxide (NO), and other growth factors involved in 
injury and in fibrogenesis of the liver (Fig. 4).44 
Cholangiocytes communicate and interact with other cells 
in the liver.51 Reactive cholangiocytes secrete mediators and 
immune factors that stimulate and activate several cellular 
subtypes. Cholangiocytes produce IL-1, IL-6, IL-8, and IFN-γ, 
which regulate the immune activity of polymorphonuclear cells, 
Kupffer cells, and T cells. ET-1, platelet-derived growth factor 
BB, transforming growth factor b2,51 connective tissue growth 
factor, and NO and produced by cholangiocytes and stimulate 
subepithelial stellate cells or myofibroblasts, leading to repara-
tive processes and/or fibrosis in the liver.44,45,51 
CHOLANGIOCYTE VERSATILITY: ESPECIALLY  
CHOLESTEROL METABOLISM
Table 2 emphasizes the variety of roles that cholangiocytes 
play. This list highlights not only the complexity of these cells, 
but also serves as a reminder of how little we truly know about 
them. Cholangiocytes are versatile cells involved in secretory 
and absorptive functions that modify the composition of bile. 
Cholangiocytes express proteins involved in drug or xenobiotics 
metabolism, cholesterol biosynthesis and transport, mucin se-
cretion, glucose transport, and apolipoprotein synthesis.1,2,13 The 
role of these proteins was well known for a long time, therefore 
I will not be mentioning the role of those proteins in this review. 
Recently cholesterol transporters and nuclear hormone receptors 
associated lipid metabolism investigated in many studies. 
Bile contains cholesterol, and thus the concentration of bile 
within the gallbladder results in high cholesterol levels in this 
organ.52,53 This facilitates cholesterol gallstone formation and 
cholesterolosis of the gallbladder wall.54,55 GBECs are exposed to 
high and fluctuating biliary cholesterol concentrations on their 
apical surfaces. They absorb biliary cholesterol via both passive 
and active mechanisms,56,57 but the fate of this absorbed choles-
terol is unclear. Cholesterol release from peripheral tissues, pri-
marily from macrophage-derived foam cells, is the first step in 
a process called “reverse cholesterol transport.”58,59 In this path-
way, excess cholesterol present in peripheral tissue cells is incor-
porated into high density lipoproteins, which deliver the excess 
cholesterol to the liver for excretion, either directly or indirectly 
by transfer to low density lipoprotein.60 A number of different 
mechanisms participate in transporting cholesterol from cells 
to extracellular acceptor lipoproteins. These cholesterol efflux 
pathways include unmediated diffusion61 and protein mediated 
transport by scavenger receptor BI or ATP-binding cassette 
transporter A1 (ABCA1).62,63 ATP binding cassette transporter 
G5 and ABCG8 form heterodimers that are expressed on the 
canalicular membranes of hepatocytes, where they excrete cho-
lesterol into bile.64,65 It has been suggested that ABCG5/ABCG8 
play a role in sterol flux at the apical pole of polarized epithelial 
cells in the liver. The unloading of cellular cholesterol onto cho-
lesterol acceptors66 is also likely to be important in maintaining 
cholesterol homeostasis within the gallbladder wall and in the 
gallbladder lumen. The relative contributions of basolateral and 
apical disposition of cholesterol by GBECs is likely to be impor-
tant in determining aberrant cholesterol disposition in the wall 
Table 2. Cholangiocyte Versatility53-55,70
Drug metabolizing enzymes
    Cytochrome P450 1A, 2E1, 3A
    Glutathione S-transferase
Drug efflux transporters
    P-glycoprotein
    MRP-1, MRP-3
    Cytokines
    IL-1b, IL-6
    TNF-α
    Cytokine-induced neutrophil chemoattractant (CINC)
Sterol metabolism enzymes
    HMG-CoA reductase
    Cholesterol 7-α hydroxylase
Mucins
    MUC3, MUC5B, MUC6
Growth factors
    EGF, HGF, PDGF
Miscellaneous
    Apolipoproteins
    Sodium-dependent glucose transporter (SGLT1)
    Facilitative glucose transporter (GLUT1)
    Reverse cholesterol transporter (ABCA1)
    ABCG5, G8
MRP, multidrug resistance protein; IL, interleukin; TNF; tumor necro-
sis factor; HMG, 3-hydroxy-3-methylglutaryl; MUC, mucin; EGF, epi-
dermal growth factor; HGF, hepatocyte growth factor; PDGF, platelet-
derived growth factor; ABCG, ATP binding cassette transporter G.
694  Gut and Liver, Vol. 10, No. 5, September 2016
and lumen of gallbladder. It has been previously reported that 
ABCA1 is expressed on the basolateral membranes of cultured 
dog GBECs, where it mediates cholesterol efflux via a liver X 
receptor a/retinoid X receptor ligand-sensitive mechanism.55,67,68 
The mechanisms involved in apical cholesterol flux in gall-
bladder epithelium are unknown, but are likely to involve 
ABCG5/ABCG8.53,54 Little is known regarding the existence and 
function of ABCA1, ABCG5, and ABCG8 in human GBECs. The 
sterol transporters ABCA1, ABCG5, and ABCG8 may play a role 
in the pathogenesis of human cholesterol associated gallbladder 
diseases. Inflammation appears to be a key factor that increases 
ABCA1 expression and activity in the human gallbladder.53,54,69,70
In addition, it also has been demonstrated that ligands of per-
oxisome proliferator-activated receptor modulate inflammation 
and affect ABCA1 expression in GBEC. This evidence suggests 
that GBECs have a perfect system for cholesterol transport.71-73
CLINICAL IMPLICATIONS
Cholangiopathies are heterogeneous etiology, but share two 
major features: (1) dysregulated balance between cell prolifera-
tion and survival; (2) selectively target either small or large bile 
ducts. The two most common cholangiopathies are PBC and 
PSC.74
Cholangiocyte heterogeneity that two different (small and 
large) cholangiocyte subpopulations exist, which differ in mor-
phological and biological aspects. Cholangiopathies target either 
small or large bile ducts.74
Cholangiocyte functional activity is regulated by secretin, 
which induces HCO3
– in bile by the activation of the AE2 ex-
changer. AE2 knockout animals develop a PBC-like phenotype. 
A variant of the AE2 gene discriminate patients with slower 
progression of PBC.7,10,13
Cholangiocyte biology and response to injury is regulated 
by bile acids in conditions of cholestasis and ductopenia, bile 
acids exert cytoprotective effects. Exacerbation of liver injury 
is observed in models of PSC-like cholestasis. Ursodeoxycho-
lic acid (UDCA) is the only compound to show some effects in 
PBC, whereas limited effects are observed in PSC. Alternative 
therapies for cholestatic liver diseases is required. Two bile acids 
derivatives as obeticholic acid (OCA) and nor-ursodeoxycholic 
acid (nor-UDCA) show promising results recently.75 
OCA is a semisynthetic analogue of chenodeoxycholic acid 
that possesses a strong farnesoid X receptor (FXR) affinity. 
Endogenous bile acids bind to FXR, which in turn represses or 
induces the expression of various genes involved in their syn-
thesis and secretion, such as cytochrome P450 7A1 (CYP7A1), 
bile salt export pump, and sodium-taurocholate cotransporting 
polypeptide. Chenodeoxycholic acid is the most potent en-
dogenous FXR ligand (with a 100-fold less affinity than OCA) 
whereas UDCA has no affinity.76,77 
Nor-UDCA, a C(23) homologue of UCDA, which is novel 
candidate for the therapy of cholangiopathies able to amelio-
rate sclerosing cholangitis in Mdr2 knockout mice. Nor-UDCA 
actions are following: increased hydrophilicity of bile acids; 
stimulated bile flow with flushing of injured bile ducts, and de-
toxification and elimination routes for bile acids.78,79
Cholangiocytes express both adrenergic and cholinergic re-
ceptors. The autonomic innervation: (1) sustains cholangiocyte 
proliferation and prevent apoptosis in response to injury; (2) 
maintain an adequate bile acids transporter (ASBT) in cholan-
giocytes. Development of non-anastomotic biliary strictures in 
the transplanted liver occurs as a consequence of impaired he-
patocellular transporters.74,75
Cholangiocytes express estrogen receptors, which exert cy-
toprotective effects and sustain their response to injury. PBC is 
more frequent in women, and its clinical breakthrough is often 
after menopause. Estrogen receptor expression is markedly re-
duced in late stage PBC.80-82
Reactive cholangiocytes synthesize and locally release endog-
enous opioid peptides, which inhibit their biological response 
to injury. Endogenous opioid peptides contribute to the genesis 
of pruritus in cholestatic patients; the administration of opiate-
antagonists is effective in reducing pruritus in those patients.83-85
Reactive cholangiocytes synthesize and locally release sero-
tonin, which inhibits their biological response to injury. Admin-
istration of sertraline resulted effective in ameliorating pruritus 
in patients with PBC. Altered response to the activation sero-
tonin receptors is malignant cholangiocytes.83,86-88
Cholangiocyte release IGF-1 and VEGF in response to injury; 
they stimulate cholangiocyte biological response to injury. IGF-
1 and VEGF stimulate cholangiocarcinoma cell growth. VEGF 
allows the expansion of the PBP (peribiliary vascular plexus). 
Progression of PBC and PSC is associated with an upcoming re-
duction of the PBP around bile ducts. Antiangiogenic therapies 
may be effective in cholangiocarcinoma. Measurement of biliary 
IGF-1 levels in patients with biliary strictures discriminate be-
tween cholangiocarcinoma and other causes of biliary obstruc-
tion.89-91
The activation of the GLP-1 receptor in cholangiocytes sus-
tain proliferation and prevents apoptosis. GLP-1 analogues are 
available as novel tools in the therapy of diabetes in humans. 
Possible effects in preventing bile duct loss observed in PBC pa-
tients.92
In response to bacterial products, auto-antibodies and cyto-
kines, cholangiocytes express adhesion molecule and release 
leuco-attractant cytokines. Cytokines impair cholangiocyte 
functions. In the course of cholangiopathies, cholangiocytes are 
exposed to bacterial products like LPS or auto-antibodies.93-95
Monoclonal antibodies is a possible therapeutic tool to treat 
cholangiopathies.96 Rituximab has been tested in six PBC pa-
tients who have an incomplete response to UDCA.97 Based 
on genetic association between the IL-2, IL-23 pathways and 
PBC,98,99 ustekinumab, an anti-p40 monoclonal antibody is cur-
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rently under way.
BTT1023 is a human monoclonal antibody targeting the 
vascular adhesion protein-1, a molecule that has been shown 
to stimulate the recruitment of effector lymphocytes to the liver 
through the upregulation of the endothelial cell adhesion mol-
ecule MadCAM-1.100,101 Simtuzumab is directed against the lysyl 
oxidase-like protein 2, an enzyme that favors the cross-linking 
of collagen and elastin fibers.102 These two monoclonal antibod-
ies are investigated in PSC patients.
CONCLUSIONS 
An overview of the current state of knowledge regarding 
the biology of the cholangiocyte has been summarized in this 
review. Cholangiocytes are versatile cells involved in transport 
processes that modify the composition and volume of bile. 
Cholangiocytes undergo proliferation and programmed cell 
death in response to certain stimuli, and they are functionally 
and morphologically heterogeneous. Finally, cholangiocytes 
participate in multiple immune responses. All of these cholan-
giocyte functions are relevant, because they provide insight into 
the pathophysiology of cholangiopathies.
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